IP Library Granted Patent US 9,681,942
Granted Patent B2
US 9,681,942 · App. 12/608,249 · Granted Jun 20, 2017

Method for prevention of rejection and sever encapsulation of a supportive or functioning implant

Inventor: Gholam A. Peyman (Sun City, AZ)
A61F2/148A61F7/007A61F9/00834A61F2/14A61F2/142A61F9/008A61F9/009A61F9/0079A61F9/00827A61F9/00838A61F2007/0004A61F2007/0054A61F2009/0088A61F2009/00853A61F2009/00872A61N5/062
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,681,942
App. No.
12/608,249
Granted
Jun 20, 2017
Kind
B2
Abstract

A method of preventing rejection of an implant in the eye, includes forming a flap in the cornea of the eye, inserting an implant under the flap, cross linking corneal tissue surrounding an implant to make the corneal tissue surrounding an implant less vulnerable to enzymatic degradation, inserting polymeric material under the corneal flap so as to overlie corneal tissue, compressing a layer of the cornea from outside using a lens having a predetermined curvature to correct refractive error of the cornea, and cross linking corneal tissue that the polymeric material overlies.

Claims (7)

1. A method of preventing rejection of an implant in the eye, comprising:

forming a flap in the cornea of the eye, wherein said forming a flap includes cutting the flap with one of a micro-keratome and a femto-second laser, the flap being cut so as to have a diameter between 2 mm-12 mm and a thickness of 50 microns to 400 microns;

raising the flap so as to expose stromal tissue of the cornea;

applying a cross linking material in the form of Riboflavin to the stromal tissue of the cornea under the flap;

inserting an implant under the flap so as to overlie the stromal tissue of the cornea;

covering at least a central portion of the implant with the flap; and

after said inserting the implant under the flap, cross linking corneal tissue vulnerable to enzymatic degradation surrounding the implant to decrease the vulnerability of corneal tissue surrounding the implant to enzymatic degradation, to make the corneal tissue surrounding the implant less likely to be invaded by migrating cells, and to prevent encapsulation around the implant.

Continuity (5)
Continuation In Part 11676793 · Feb 20, 2007
Continuation In Part 11446065 · Jun 1, 2006
Continuation In Part 11070659 · Mar 2, 2005
Continuation In Part 09986141 · Nov 7, 2001
Related Publication 20100114109A1 · May 6, 2010